Mustang Bio Launches CRISPR/Cas9 CAR-T Collaborations with Harvard, BIDMC
Mustang Bio said today it plans to develop CRISPR/Cas9 -enhanced chimeric antigen receptor engineered T-cell (CAR-T) therapies for cancer through a license from Harvard University and a research collaboration agreement with Beth Israel Deaconess Medical Center (BIDMC). The value of both agreements was not disclosed. CRISPR stands for clustered regularly interspaced short palindromic repeats. Mustang Bio, a subsidiary of Fortress Biotech, said that technologies related to the development of off-the-shelf CAR-T, as well as CRISPR/Cas9 gene-editing platforms, will be used in combination with Mustang’s CAR-T cell therapies toward treatments for hematologic malignancies and solid tumors under the company’s licensing agreement with Harvard’s Office of Technology Development. Mustang’s pipeline includes six CAR-T therapy candidates toward the development of CRISPR-enhanced CAR-T therapies targeting hematologic malignancies and solid tumor cancers. Furthest along are two Phase I candidates—Mustang’s lead CAR-T therapy, the glioblastoma multiforme treatment MB-101, and MB-102, which is ...
Original Article: Mustang Bio Launches CRISPR/Cas9 CAR-T Collaborations with Harvard, BIDMC
